Skip to main content
TipRanks
Go Ultimate75% OFF

Trans Genic Inc. (2342) AI Stock Analysis

0 Followers
JP:2342

Trans Genic Inc.

(TSE/TYO:2342)

Select Model
Rating:43Neutral
Price Target:JPY 196.00â–²(7.69% Upside)
Action:reiterated
Date:11/14/26

The overall score is low, primarily driven by weak cash flow generation and persistent negative free cash flow, which raises concerns about financial sustainability. This is compounded by a bearish technical picture with the stock in a clear downtrend and a very high P/E ratio that is not supported by current earnings or a dividend. A modestly stable balance sheet and signs of operational recovery prevent a lower score.

Positive Factors
Moderate leverageModerate and improving leverage gives Trans Genic a more serviceable financial foundation than a highly indebted balance sheet would provide. Substantial equity relative to assets can support operations and preserve flexibility while management works to stabilize profitability and cash generation.
Negative Factors
Volatile profitabilityRecurring net losses and sharp swings in profitability weaken confidence in the durability of the business model’s earnings. Even with improved operating results in 2026, inconsistent bottom-line performance can constrain reinvestment, reduce financial resilience, and make future earnings less predictable.

Trans Genic Inc. (2342) vs. iShares MSCI Japan ETF (EWJ)

-25%0%25%50%75%100%125%150%JP:2342-13.74%EWJ+14.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 3.15B
Dividend Yield
―
Average Volume (3M)
48.05K
Price to Earnings (P/E)
-165.2
Beta (1Y)
1.28
Revenue Growth
8.53%
EPS Growth
97.93%
Country
Japan
Employees
227
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Trans Genic Inc. Business Overview & Revenue Model

Company Description

Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Inves...

How the Company Makes Money

null

Trans Genic Inc. Financial Statement Overview

Summary

Financial performance is mixed. The income statement shows a recovery with a return to positive operating profit and narrowing net losses, but profitability remains inconsistent. The balance sheet is stable with manageable leverage (debt-to-equity of 0.44). However, cash flow is a significant concern, with persistent negative free cash flow and low operating cash flow coverage, indicating ongoing cash burn.

Income Statement

45Neutral

Balance Sheet

55Neutral

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue13.17B13.17B13.01B13.08B11.43B12.58B
Gross Profit2.43B2.43B2.17B2.25B1.99B3.84B
EBITDA293.56M293.56M-64.37M253.62M158.37M2.07B
Net Income-77.27M-77.27M-1.09B4.08M-409.67M1.88B
Balance Sheet
Total Assets9.74B9.74B9.59B9.84B10.68B10.44B
Cash, Cash Equivalents and Short-Term Investments2.13B2.13B2.56B2.48B3.46B4.62B
Total Debt2.09B2.09B2.58B2.26B2.43B1.86B
Total Liabilities4.90B4.90B4.73B3.84B4.56B3.80B
Stockholders Equity4.78B4.78B4.76B5.89B6.02B6.53B
Cash Flow
Free Cash Flow0-42.55M-81.35M-658.12M-1.74B1.26B
Operating Cash Flow025.91M94.10M-392.45M-1.43B1.79B
Investing Cash Flow050.87M-287.85M-280.93M-216.02M981.87M
Financing Cash Flow0-518.46M265.10M-342.69M484.98M-1.18B

Trans Genic Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price182.00

Price Trends

50DMA230.98Negative
100DMA228.66Negative
200DMA248.91Negative

Market Momentum

MACD-8.29Positive
RSI33.22Neutral
STOCH8.02Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Negative. The current price of 182.00 is below the 20-day moving average (MA) of 209.50, below the 50-day MA of 230.98, and below the 200-day MA of 248.91, indicating a bearish trend. The MACD of -8.29 indicates Positive momentum. The RSI at 33.22 is Neutral, neither overbought nor oversold. The STOCH value of 8.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2342.

Trans Genic Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:2342 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6190JP:619054NeutralJPY 1.02B-95.40――-9.37%96.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4880JP:488049NeutralJPY 5.40B54.73―1.84%-9.94%―
JP:2342JP:234243NeutralJPY 3.07B-165.15――8.53%97.93%
JP:4978JP:497842NeutralJPY 11.33B-24.37――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 26.32B-73.22――17.05%10.47%
JP:7776JP:777626UnderperformJPY 6.15B-5.03――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%JP:2342JP:4880JP:4978JP:6190JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:2342 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:2342Trans Genic Inc.182.00-44.00-19.47%
JP:4880CellSource Co., Ltd.272.00-225.00-45.27%
JP:4978ReproCELL Inc.106.00-52.00-32.91%
JP:6190PhoenixBio Co., Ltd.249.00-157.00-38.67%
JP:7774Japan Tissue Engineering Co., Ltd.648.00170.0035.56%
JP:7776CellSeed Inc.155.00-225.00-59.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026